What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Medical Device

In Vitro Diagnostics Biotechnology Equipment

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1455580

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1455580

APAC PCR-based Infectious Diseases Market - Industry Trends and Forecast to 2032

PUBLISHED: February 1, 2024

PAGES: 258 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

The Asia-Pacific PCR-based infectious diseases market is expected to reach USD 1,648,287.10 thousand by 2031, from USD 948,935.27 thousand in 2023, growing with a CAGR of 7.4% in the forecast period of 2024 to 2031.

Market Segmentation

Asia-Pacific PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031

Overview of Asia-Pacific PCR-based Infectious Diseases Market Dynamics

Driver
Increasing PCR-based research activities
Restraint
High cost of PCR test services
Opportunity
Disease surveillance for early detection and monitoring of infectious diseases

Market Players

Some of the major market players operating in the Asia-Pacific PCR-based infectious diseases market are:

DNA Labs India
DrSafeHands
Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
Max Lab
MicroGen Diagnostics
pathlab
The Washington Travel Clinic
Clarewell Clinics
AZOVA
One Life Home Health Care Center
LalPathLabs

1 INTRODUCTION 44

1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET 44
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 46
1.6 MARKETS COVERED 46

2 MARKET SEGMENTATION 49

2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.6 MULTIVARIATE MODELLING 56
2.7 MARKET APPLICATION COVERAGE GRID 57
2.8 TEST TYPE LIFELINE CURVE 58
2.9 DBMR MARKET POSITION GRID 59
2.10 VENDOR SHARE ANALYSIS 60
2.11 SECONDARY SOURCES 61
2.12 ASSUMPTIONS 61

3 EXECUTIVE SUMMARY 62

4 PREMIUM INSIGHTS 65

4.1 PESTEL ANALYSIS 66
4.2 PORTER'S FIVE FORCES 67

5 MARKET OVERVIEW 68

5.1 DRIVERS 70
- 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 70
- 5.1.2 RISING CASES OF INFECTIOUS DISEASES 70
- 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 71
5.2 RESTRAINTS 72
- 5.2.1 HIGH COST OF PCR TEST SERVICES 72
- 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 73
5.3 OPPORTUNITIES 74
- 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 74
- 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 74
- 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 75
5.4 CHALLENGES 76
- 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 76
- 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 76

6 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 78

6.1 OVERVIEW 79
6.2 TUBERCULOSIS PCR TEST 85
6.3 HEPATITIS PCR TEST 85
- 6.3.1 HEPATITIS C PCR TEST 86
- 6.3.2 HEPATITIS B PCR TEST 86
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 87
6.5 INFLUENZA PCR TEST 87
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 88
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 88
6.8 GONORRHEA PCR TEST 89
6.9 SALMONELLOSIS PCR TEST 89
6.10 ROTAVIRUS PCR TEST 90
6.11 BORDETELLA PCR TEST 90
6.12 H. PYLORI PCR TEST 91
6.13 SARS (COVID-19) PCR TEST 91
6.14 NOROVIRUS PCR TEST 92
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 92
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 93
6.17 ENTEROCOCCUS PCR TEST 93
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 94
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 94
6.20 OTHERS PCR TEST 95

7 ASIA - PACIFIC PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 96

7.1 OVERVIEW 97
7.2 VIRAL INFECTION 100
- 7.2.1 SARS (COVID-19) INFECTION 100
- 7.2.2 ROTAVIRUS INFECTION 100
- 7.2.3 NOROVIRUS INFECTION 100
- 7.2.4 OTHERS 101
7.3 RESPIRATORY TRACT INFECTION 101
- 7.3.1 INFLUENZA 101
- 7.3.2 TUBERCULOSIS 101
- 7.3.3 BORDETELLA 102
7.4 SEXUALLY TRANSMITTED INFECTION 102
- 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 103
- 7.4.2 GONORRHEA 103
- 7.4.3 HEAPTITIS 103
- 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 103
- 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 103
- 7.4.6 MYCOPLASMA GENITALIUM (MG) 103
- 7.4.7 OTHERS 103
7.5 HOSPITAL ACQUIRED INFECTIONS 104
- 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 104
- 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 104
- 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 105
- 7.5.4 OTHERS 105
7.6 OTHER INFECTIONS 105
- 7.6.1 SALMONELLOSIS 105
- 7.6.2 H. PYLORI 106
- 7.6.3 ENTEROCOCCUS INFECTIONS 106
- 7.6.4 OTHERS 106

8 ASIA - PACIFIC PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 107

8.1 OVERVIEW 108
8.2 VIRAL 111
8.3 BACTERIAL 111
8.4 FUNGAL 112
8.5 PROTOZOA 112
8.6 OTHERS 113

9 ASIA - PACIFIC PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 114

9.1 OVERVIEW 115
9.2 RT PCR 118
9.3 MULTIPLEX PCR 118
9.4 OTHERS 119

10 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 120

10.1 OVERVIEW 121
10.2 GERIATRIC 124
10.3 PEDIATRIC 124
10.4 ADULTS 125

11 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 126

11.1 OVERVIEW 127
11.2 LABORATORY BASED TESTING 130
11.3 POINT OF CARE TESTING 130

12 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 131

12.1 OVERVIEW 132
12.2 DIAGNOSTIC CENTERS 135
12.3 HOSPITAL 135
12.4 CLINICS 136
12.5 COMMUNITY HEALTH CENTERS 136
12.6 ACADEMIC AND RESEARCH INSTITUTES 137
12.7 HOME HEALTHCARE 137
12.8 OTHERS 138

13 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 139

13.1 ASIA PACIFIC 142
- 13.1.1 CHINA 152
- 13.1.2 AUSTRALIA 160
- 13.1.3 JAPAN 168
- 13.1.4 INDIA 176
- 13.1.5 SOUTH KOREA 184
- 13.1.6 SINGAPORE 192
- 13.1.7 MALAYISA 200
- 13.1.8 THAILAND 208
- 13.1.9 INDONESIA 216
- 13.1.10 PHILIPPINES 224
- 13.1.11 REST OF ASIA-PACIFIC 232

14 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 235

14.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 235

15 SWOT ANALYSIS 236

16 COMPANY PROFILE 237

16.1 MICROGEN DIAGNOSTICS 237
- 16.1.1 COMPANY SNAPSHOT 237
- 16.1.2 SERVICE PORTFOLIO 237
- 16.1.3 RECENT DEVELOPMENTS 238
16.2 MAX LAB 239
- 16.2.1 COMPANY SNAPSHOT 239
- 16.2.2 SERVICE PORTFOLIO 239
16.3 DNA LABS INDIA 241
- 16.3.1 COMPANY SNAPSHOT 241
- 16.3.2 SERVICE PORTFOLIO 241
- 16.3.3 RECENT DEVELOPMENT 242
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 243
- 16.4.1 COMPANY SNAPSHOT 243
- 16.4.2 SERVICE PORTFOLIO 243
- 16.4.3 RECENT DEVELOPMENT 244
16.5 LALPATHLABS 245
- 16.5.1 COMPANY SNAPSHOT 245
- 16.5.2 REVENUE ANALYSIS 245
- 16.5.3 PRODUCT PORTFOLIO 246
- 16.5.4 RECENT DEVELOPMENTS 246
16.6 AZOVA 247
- 16.6.1 COMPANY SNAPSHOT 247
- 16.6.2 PRODUCT PORTFOLIO 247
- 16.6.3 RECENT DEVELOPMENTS 247
16.7 CLAREWELL CLINICS 248
- 16.7.1 COMPANY SNAPSHOT 248
- 16.7.2 PRODUCT DESCRIPTION 248
- 16.7.3 RECENT DEVELOPMENTS 248
16.8 DRSAFEHANDS 249
- 16.8.1 COMPANY SNAPSHOT 249
- 16.8.2 SERVICE PORTFOLIO 249
- 16.8.3 RECENT DEVELOPMENT 249
16.9 ONE LIFE HOME HEALTH CARE CENTER 250
- 16.9.1 COMPANY SNAPSHOT 250
- 16.9.2 PRODUCT DESCRIPTION 250
- 16.9.3 RECENT DEVELOPMENTS 250
16.10 PATHLAB 251
- 16.10.1 COMPANY SNAPSHOT 251
- 16.10.2 SERVICE PORTFOLIO 251
- 16.10.3 RECENT DEVELOPMENT 251
16.11 THE WASHINGTON TRAVEL CLINIC 252
- 16.11.1 COMPANY SNAPSHOT 252
- 16.11.2 SERVICE PORTFOLIO 252
- 16.11.3 RECENT DEVELOPMENT 253

17 QUESTIONNAIRE 254

18 RELATED REPORTS 258

LIST OF TABLES

TABLE 1 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 61
TABLE 2 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 62
TABLE 3 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 63
TABLE 4 ASIA - PACIFIC TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 5 ASIA - PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 6 ASIA - PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 65
TABLE 7 ASIA - PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 65
TABLE 8 ASIA - PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 65
TABLE 9 ASIA - PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 10 ASIA - PACIFIC INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 11 ASIA - PACIFIC HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 12 ASIA - PACIFIC CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 13 ASIA - PACIFIC GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 14 ASIA - PACIFIC SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 15 ASIA - PACIFIC ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 69
TABLE 16 ASIA - PACIFIC BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 69
TABLE 17 ASIA - PACIFIC H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 70
TABLE 18 ASIA - PACIFIC SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 70
TABLE 19 ASIA - PACIFIC NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 71
TABLE 20 ASIA - PACIFIC C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 71
TABLE 21 ASIA - PACIFIC CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 72
TABLE 22 ASIA - PACIFIC ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 72
TABLE 23 ASIA - PACIFIC MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 73
TABLE 24 ASIA - PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 73
TABLE 25 ASIA - PACIFIC OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 74
TABLE 26 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 78
TABLE 27 ASIA - PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 79
TABLE 28 ASIA - PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 79
TABLE 29 ASIA - PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 80
TABLE 30 ASIA - PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 80
TABLE 31 ASIA - PACIFIC SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 81
TABLE 32 ASIA - PACIFIC SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 81
TABLE 33 ASIA - PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 83
TABLE 34 ASIA - PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 83
TABLE 35 ASIA - PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 84
TABLE 36 ASIA - PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 84
TABLE 37 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 89
TABLE 38 ASIA - PACIFIC VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
TABLE 39 ASIA - PACIFIC BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
TABLE 40 ASIA - PACIFIC FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 41 ASIA - PACIFIC PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 42 ASIA - PACIFIC OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
TABLE 43 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 96
TABLE 44 ASIA - PACIFIC RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 45 ASIA - PACIFIC MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 46 ASIA - PACIFIC OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 98
TABLE 47 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 102
TABLE 48 ASIA - PACIFIC GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 49 ASIA - PACIFIC PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 50 ASIA - PACIFIC ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 104
TABLE 51 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 108
TABLE 52 ASIA - PACIFIC LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 109
TABLE 53 ASIA - PACIFIC POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 109
TABLE 54 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND) 113
TABLE 55 ASIA - PACIFIC DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
TABLE 56 ASIA - PACIFIC HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
TABLE 57 ASIA - PACIFIC CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
TABLE 58 ASIA - PACIFIC COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
TABLE 59 ASIA - PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
TABLE 60 ASIA - PACIFIC HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
TABLE 61 ASIA - PACIFIC OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 117
TABLE 62 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 121
TABLE 63 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 122
TABLE 64 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 123
TABLE 65 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 124
TABLE 66 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 125
TABLE 67 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 125
TABLE 68 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 125
TABLE 69 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 125
TABLE 70 ASIA-PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 126
TABLE 71 ASIA-PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 126
TABLE 72 ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 127
TABLE 73 ASIA-PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 127
TABLE 74 ASIA-PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 128
TABLE 75 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 128
TABLE 76 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 129
TABLE 77 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 129
TABLE 78 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 129
TABLE 79 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 130
TABLE 80 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 131
TABLE 81 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 132
TABLE 82 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 133
TABLE 83 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 134
TABLE 84 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 134
TABLE 85 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 134
TABLE 86 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 134
TABLE 87 CHINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 135
TABLE 88 CHINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 135
TABLE 89 CHINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 136
TABLE 90 CHINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 136
TABLE 91 CHINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 137
TABLE 92 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 137
TABLE 93 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 137
TABLE 94 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 138
TABLE 95 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 138
TABLE 96 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 138
TABLE 97 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 139
TABLE 98 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 140
TABLE 99 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 141
TABLE 100 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 142
TABLE 101 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 142
TABLE 102 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 142
TABLE 103 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 142
TABLE 104 AUSTRALIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 143
TABLE 105 AUSTRALIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 143
TABLE 106 AUSTRALIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 144
TABLE 107 AUSTRALIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 144
TABLE 108 AUSTRALIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 145
TABLE 109 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 145
TABLE 110 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 145
TABLE 111 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 146
TABLE 112 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 146
TABLE 113 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 146
TABLE 114 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 147
TABLE 115 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 148
TABLE 116 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 149
TABLE 117 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 150
TABLE 118 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 150
TABLE 119 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 150
TABLE 120 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 150
TABLE 121 JAPAN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 151
TABLE 122 JAPAN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 151
TABLE 123 JAPAN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
TABLE 124 JAPAN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
TABLE 125 JAPAN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 153
TABLE 126 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 153
TABLE 127 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 153
TABLE 128 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 154
TABLE 129 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 154
TABLE 130 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 154
TABLE 131 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 155
TABLE 132 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 156
TABLE 133 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 157
TABLE 134 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 158
TABLE 135 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 158
TABLE 136 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 158
TABLE 137 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 158
TABLE 138 INDIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 159
TABLE 139 INDIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 159
TABLE 140 INDIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
TABLE 141 INDIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
TABLE 142 INDIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 161
TABLE 143 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 161
TABLE 144 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 161
TABLE 145 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 162
TABLE 146 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 162
TABLE 147 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 162
TABLE 148 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 163
TABLE 149 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 164
TABLE 150 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 165
TABLE 151 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 166
TABLE 152 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 166
TABLE 153 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 166
TABLE 154 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 166
TABLE 155 SOUTH KOREA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 167
TABLE 156 SOUTH KOREA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 167
TABLE 157 SOUTH KOREA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
TABLE 158 SOUTH KOREA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
TABLE 159 SOUTH KOREA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 169
TABLE 160 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 169
TABLE 161 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 169
TABLE 162 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 163 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 170
TABLE 164 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 170
TABLE 165 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 171
TABLE 166 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 172
TABLE 167 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 173
TABLE 168 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 174
TABLE 169 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 174
TABLE 170 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 174
TABLE 171 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 174
TABLE 172 SINGAPORE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 175
TABLE 173 SINGAPORE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 175
TABLE 174 SINGAPORE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
TABLE 175 SINGAPORE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
TABLE 176 SINGAPORE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 177
TABLE 177 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 177
TABLE 178 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 177
TABLE 179 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 178
TABLE 180 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 178
TABLE 181 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 178
TABLE 182 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 179
TABLE 183 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 180
TABLE 184 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 181
TABLE 185 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 182
TABLE 186 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 182
TABLE 187 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 182
TABLE 188 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 182
TABLE 189 MALAYSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 183
TABLE 190 MALAYSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 183
TABLE 191 MALAYSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 184
TABLE 192 MALAYSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 184
TABLE 193 MALAYSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 185
TABLE 194 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 185
TABLE 195 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 185
TABLE 196 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 186
TABLE 197 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 186
TABLE 198 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 186
TABLE 199 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 187
TABLE 200 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 188
TABLE 201 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 189
TABLE 202 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 190
TABLE 203 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 190
TABLE 204 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 190
TABLE 205 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 190
TABLE 206 THAILAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 191
TABLE 207 THAILAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 191
TABLE 208 THAILAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 192
TABLE 209 THAILAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 192
TABLE 210 THAILAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 193
TABLE 211 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 193
TABLE 212 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 193
TABLE 213 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 194
TABLE 214 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 194
TABLE 215 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 194
TABLE 216 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 195
TABLE 217 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 196
TABLE 218 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 197
TABLE 219 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 220 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 198
TABLE 221 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 198
TABLE 222 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 198
TABLE 223 INDONESIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 199
TABLE 224 INDONESIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 199
TABLE 225 INDONESIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 200
TABLE 226 INDONESIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 200
TABLE 227 INDONESIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 201
TABLE 228 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 201
TABLE 229 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 201
TABLE 230 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 231 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 202
TABLE 232 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 202
TABLE 233 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 203
TABLE 234 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 204
TABLE 235 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 205
TABLE 236 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 206
TABLE 237 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 206
TABLE 238 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 206
TABLE 239 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 206
TABLE 240 PHILIPPINES VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 207
TABLE 241 PHILIPPINES RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 207
TABLE 242 PHILIPPINES SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 208
TABLE 243 PHILIPPINES HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 208
TABLE 244 PHILIPPINES OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 209
TABLE 245 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 209
TABLE 246 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 209
TABLE 247 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 248 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 210
TABLE 249 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 210
TABLE 250 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 211
TABLE 251 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 212
TABLE 252 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 213

LIST OF FIGURES

FIGURE 1 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 28
FIGURE 2 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 31
FIGURE 3 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS 32
FIGURE 4 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: ASIA - PACIFIC VS REGIONAL MARKET ANALYSIS 33
FIGURE 5 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS 33
FIGURE 6 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 36
FIGURE 8 ASIA - PACIFIC PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 38
FIGURE 9 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS 39
FIGURE 10 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 43
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031 44
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET 48
FIGURE 14 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023 58
FIGURE 15 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND) 59
FIGURE 16 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031) 59
FIGURE 17 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE 60
FIGURE 18 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023 76
FIGURE 19 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND) 77
FIGURE 20 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031) 77
FIGURE 21 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE 78
FIGURE 22 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023 87
FIGURE 23 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND) 88
FIGURE 24 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031) 88
FIGURE 25 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE 89
FIGURE 26 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023 94
FIGURE 27 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND) 95
FIGURE 28 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031) 95
FIGURE 29 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE 96
FIGURE 30 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023 100
FIGURE 31 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 101
FIGURE 32 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031) 101
FIGURE 33 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE 102
FIGURE 34 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023 106
FIGURE 35 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND) 107
FIGURE 36 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031) 107
FIGURE 37 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE 108
FIGURE 38 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023 111
FIGURE 39 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND) 112
FIGURE 40 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031) 112
FIGURE 41 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE 113
FIGURE 42 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023) 119
FIGURE 43 ASIA - PACIFIC PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%) 214